Jul, 10 2018 11:14 JST

Source: Eisai

Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018


TOKYO, Jul, 10 2018 - (JCN Newswire) - Eisai Co., Ltd. announces today that the results of the Phase II clinical study (Study 201) of the anti-amyloid beta (Abeta) protofibril antibody BAN2401 will be presented in an oral session at the Alzheimer's Association International Conference (AAIC) 2018 held in Chicago from July 22 to 26, 2018. The topline results of this study were announced on July 6. This oral presentation is scheduled for July 25, 2018 at 15:30 as part of Session DT-01 "Recent Developments in Therapeutics" (14:00 to 16:00).

The slide presentation will be available concurrently with the AAIC presentation on the Investor section of the Eisai company website at www.eisai.com.

http://www.acnnewswire.com/topimg/Low_EisaiAAIC.jpg

About AAIC

The Alzheimer's Association International Conference (AAIC) is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment, and improvements in diagnosis for Alzheimer's disease. AAIC 2018 will be held in Chicago, IL at McCormick Place July 22-26. For more information about AAIC, please visit www.alz.org/aaic.

About BAN2401

BAN2401 is a humanized monoclonal antibody for Alzheimer's disease that is the result of a strategic research alliance between Eisai and BioArctic. BAN2401 selectively binds to neutralize and eliminate soluble, toxic Abeta aggregates that are thought to contribute to the neurodegenerative process in Alzheimer's disease. As such, BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer's disease pursuant to an agreement concluded with BioArctic in December 2007. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for BAN2401 and the parties amended that agreement in October 2017.

This release discusses investigational uses of BAN2401 and is not intended to convey conclusions about efficacy or safety. BAN2401 has not been approved for marketing under any health authority approval.

About the Joint Development Agreement between Eisai and Biogen for Alzheimer's Disease

Eisai and Biogen are widely collaborating on the joint development and commercialization of Alzheimer's disease treatments. Eisai serves as the lead in the co-development of elenbecestat, a BACE inhibitor, and BAN2401, an anti-Abeta protofibril antibody, while Biogen serves as the lead for co-development of aducanumab, Biogen's investigational anti-Abeta antibody for patients with Alzheimer's disease, and the companies plan to pursue marketing authorizations for the three compounds worldwide. If approved, the companies will also co-promote the products in major markets, such as the United States, the European Union and Japan.


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Latest Data on Eisai's Alzheimer's Disease / Dementia Pipeline to be Presented at Alzheimer's Association International Conference (AAIC) 2018
July 19 2018 09:38 JST
 
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ
July 18 2018 11:04 JST
 
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan
July 11 2018 15:32 JST
 
Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology
July 09 2018 14:07 JST
 
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 At 18 Months
July 06 2018 09:31 JST
 
Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series
July 04 2018 17:18 JST
 
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder
July 02 2018 15:36 JST
 
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)
June 22 2018 10:58 JST
 
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL
June 21 2018 09:51 JST
 
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research
June 14 2018 09:11 JST
 
More Press release >>

Latest Press Release


More Latest Release >>